share_log

灵康药业(603669.SH):子公司获得药物临床试验批准通知书

Lionco Pharmaceutical Group (603669.SH): Its subsidiary has obtained a notice of approval for clinical trials of drugs.

Gelonghui Finance ·  Jul 17 05:12

On July 17th, Gelonghui reported that Lionco Pharmaceutical Group (603669.SH) announced that its wholly-owned subsidiary, Hainan Lionco Pharmaceutical Co., Ltd. (referred to as "Lionco Pharmaceuticals"), recently obtained the Drug Clinical Trial Approval Notice for Esomeprazole Magnesium and Sodium Bicarbonate Mixed Dispersible Granules (I) issued by the Drug Evaluation Center (CDE) of the National Medical Products Administration. Esomeprazole magnesium and sodium bicarbonate mixed dispersible granules (I) are clinically intended for the long-term treatment of symptoms of gastroesophageal reflux disease (GERD) in patients with already cured esophagitis, prevention of recurrence and symptom control of GERD; treatment of gastric ulcers related to the use of non-steroidal anti-inflammatory drugs (NSAIDs) in patients who need continued NSAID treatment.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment